Proteomics is the large-scale study of proteins: their structure, function, interactions, and abundance within a cell, tissue, or entire organism. While the human genome contains roughly 20,000 genes, the actual number of distinct protein forms in the body is estimated at over one million, thanks to chemical modifications that happen after proteins are built. Proteomics exists to map and make sense of that complexity.
Why Proteins Matter More Than Genes Alone
Your DNA is essentially a blueprint. It tells cells which proteins to build, but it doesn’t reveal what those proteins are actually doing at any given moment. Two cells can carry identical DNA yet behave completely differently because they produce different proteins, in different amounts, at different times. A liver cell and a brain cell share the same genome, but their protein profiles are worlds apart.
Proteins are the molecules that carry out nearly every task in the body. They form the structural scaffolding of cells, speed up chemical reactions, transmit signals between organs, and defend against infection. Studying the genome tells you what’s theoretically possible. Studying the proteome tells you what’s actually happening.
One of the key reasons proteomics is so valuable is that it captures something DNA sequencing simply cannot: post-translational modifications. After a protein is assembled, the cell can chemically alter it in roughly 200 different ways, including adding phosphate groups or sugar chains. These modifications change how the protein behaves, where it goes in the cell, and whether it’s active or silent. The only way to detect these changes is through proteomic analysis.
How Scientists Analyze Proteins
The workhorse technology behind modern proteomics is mass spectrometry, an instrument that identifies molecules by measuring their mass with extreme precision. In the most common approach, called bottom-up proteomics, scientists don’t analyze whole proteins directly. Instead, they break proteins into smaller fragments called peptides using digestive enzymes, then feed those fragments into a mass spectrometer. The instrument measures the mass of each peptide and compares it against databases to figure out which proteins were present in the original sample.
Before any of that happens, the protein sample goes through several preparation steps: separating proteins from other cellular material, chemically treating them so they unfold into a consistent shape, digesting them into peptides, and cleaning up the mixture to remove salts and contaminants. The entire workflow, from sample to data, can take a full day or longer depending on how deep the analysis needs to go.
Other techniques complement mass spectrometry. X-ray crystallography and nuclear magnetic resonance spectroscopy are used in structural proteomics to determine the three-dimensional shape of proteins, which is critical for understanding how they work and how drugs might interact with them.
Branches of Proteomics
The field splits into several overlapping specialties, each with a different focus:
- Expression proteomics compares protein levels between two conditions, such as healthy tissue versus tumor tissue, to find proteins that are abnormally high, low, or entirely absent in disease.
- Structural proteomics maps the 3D architecture of proteins and protein complexes, revealing how they physically interact with each other and with other molecules.
- Functional proteomics investigates what proteins do inside the cell, including how they signal to each other, form networks, and drive molecular pathways.
The Dynamic Range Problem
One of the biggest technical hurdles in proteomics is the sheer range of protein concentrations inside a cell. The most abundant proteins can exist at ten million copies per cell, while the rarest may have just a single copy. That’s a span of seven orders of magnitude, like trying to hear a whisper during a rock concert.
Current mass spectrometers can handle about four orders of magnitude of that range, which is enough to detect roughly half of a cell’s proteins (around 5,000) in a fairly routine experiment. Going deeper gets progressively harder. Analysis of published studies shows that once you pass that halfway mark, the discovery rate drops dramatically, yielding on average 20 or fewer new proteins per hour of additional instrument time. Detecting the full proteome of a cell remains a major unsolved challenge.
Where the Human Proteome Project Stands
The Human Proteome Project, coordinated by the Human Proteome Organization, is an international effort to confirm the existence of every protein encoded by the human genome. As of 2025, the project has confidently detected 18,194 out of 19,435 predicted proteins, covering 93.6% of the human proteome. The remaining proteins are proving especially difficult to find, likely because they’re produced in tiny quantities, appear only in specific tissues, or exist for very brief periods.
Medical Applications
Proteomics has already moved from the research lab into clinical use. One landmark example is OVA1, the first FDA-cleared diagnostic test built from a panel of proteomic biomarkers. It measures five blood proteins to help assess whether a pelvic mass is likely to be ovarian cancer, giving surgeons better information before they operate. Two of those five proteins were originally discovered using proteomic mass spectrometry techniques.
Other proteomic diagnostics followed. ROMA, a two-protein blood test, also evaluates ovarian cancer risk. The prostate health index (phi) combines three protein measurements to help distinguish aggressive prostate cancer from slower-growing forms, reducing unnecessary biopsies. Mass spectrometry-based systems have also been approved for rapidly identifying bacteria and other microorganisms in clinical specimens, speeding up the process of choosing the right antibiotic for an infection.
Beyond diagnostics, proteomics is central to drug development. Understanding which proteins are active in a disease, and how their levels or modifications change, helps researchers identify drug targets and predict which patients will respond to treatment.
Machine Learning and Large-Scale Data
A single proteomics experiment can generate enormous datasets, sometimes containing measurements for thousands of proteins across hundreds of samples. Making sense of that volume of data is where machine learning comes in. Algorithms can be trained to sort samples into categories (cancerous versus healthy, for instance) based on protein patterns, or to pick out the handful of proteins most useful as diagnostic markers from a pool of thousands.
Machine learning can be applied at two stages: directly to the raw signals from the mass spectrometer, or after proteins have been identified and quantified. In the first case, the algorithm looks for spectral patterns that distinguish disease groups. In the second, it works with a list of protein abundances, essentially a spreadsheet of protein levels per sample, and learns which combinations of proteins best predict a given outcome. These approaches can also generate protein interaction networks, mapping how proteins work together in pathways that go wrong during disease.
Scale of the Field
Proteomics has grown into a substantial global industry. The market was valued at roughly $31 billion in 2025 and is projected to exceed $106 billion by 2035, expanding at nearly 13% per year. That growth is driven by increasing demand for precision diagnostics, the falling cost of mass spectrometry instruments, and the integration of proteomics into pharmaceutical research pipelines. What was once a niche academic discipline is now a core technology in medicine, agriculture, and biotechnology.